Prima BioMed (NASDAQ:IMMP) Rating Increased to Hold at Wall Street Zen

Prima BioMed (NASDAQ:IMMP) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Prima BioMed in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Prima BioMed presently has an average rating of “Sell”.

Prima BioMed Price Performance

NASDAQ:IMMP opened at $2.64 on Friday. The firm has a 50 day simple moving average of $2.84 and a 200-day simple moving average of $2.16. Prima BioMed has a 1-year low of $1.32 and a 1-year high of $3.53.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC grew its stake in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 51,574 shares of the biotechnology company’s stock after buying an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent filing with the Securities and Exchange Commission. 2.32% of the stock is currently owned by institutional investors.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.